查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950516

溶瘤病毒生产和开发服务市场（按服务类型、规模、病毒类型、合约类型、最终用户和应用划分），全球预测，2026-2032年

Oncolytic Virus Manufacturing & Development Services Market by Service Type, Scale, Virus Type, Contract Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年溶瘤病毒生产和开发服务市值为 3.6033 亿美元，预计到 2026 年将成长至 3.7637 亿美元，预计到 2032 年将达到 5.5061 亿美元，复合年增长率为 6.24%。

关键市场统计数据
基准年 2025 3.6033亿美元
预计年份：2026年 3.7637亿美元
预测年份 2032 5.5061亿美元
复合年增长率 (%) 6.24%

为相关人员提供简明扼要、全面整合的介绍，阐述影响肿瘤病毒生产和开发过程的科学、营运和监管要求。

溶瘤病毒作为治疗方法的出现，彻底改变了癌症的研究和开发，同时也对科学、生产和监管领域提出了更高的要求。如今，溶瘤病毒疗法的研发人员面临着细胞生物学、载体工程和临床应用之间错综复杂的交叉领域，需要协调上游工程和下游製程。随着治疗方法从实验室走向临床试验，生产安全、高效且可重复的病毒製剂的技术和操作复杂性显着增加，因此严格的製程控制、可靠的分析框架和可扩展的生产策略至关重要。

技术创新、联合治疗策略以及不断变化的监管要求如何重塑溶瘤病毒研发和生产中的决策

近年来，技术进步、不断更新的临床证据和市场动态重塑了研发策略，为溶瘤病毒领域带来了变革性变化。载体设计的创新，包括提高肿瘤选择性和引入免疫调节有效载荷，正在扩大治疗范围并推动生产流程的改进。同时，用于鑑定、效力测定和杂质分析的分析方法的进步，使得更科学的工艺优化和可比性评估成为可能。

评估2025年实施的关税变化对溶瘤病毒研发和生产网络在供应链、采购和营运方面的累积影响

美国自2025年起实施的关税政策不断升级，为支持溶瘤病毒生产的国际供应链带来了新的挑战。采购专用原料、一次性组件和特定设备的成本上升和挑战日益加剧，迫使各企业重新评估供应商结构和物流模式。为此，许多研发商和服务供应商正加紧努力，实现供应商多元化，合格替代材料，并重新谈判合约条款，以在确保供应连续性的同时控制不断上涨的成本。

将服务类型、病毒式传播平台、最终用户、用例、合约模式和规模需求与开发优先顺序相匹配的实用细分洞察

精细化的市场区隔框架识别出溶瘤病毒市场中技术需求、采购选择和合作伙伴模式的差异领域。就服务类型而言，需求涵盖分析服务、细胞株开发、填充、生产、製程开发、纯化、品管和法规支援等各个面向。生产本身又根据临床、商业和临床前阶段进行区分，其中临床生产进一步细分为I/II期和III期需求。每种服务类型都有不同的性能指标要求：分析服务需要提供高灵敏度和特异性的检测方法；细胞株开发需要稳定性和可扩展性；填充表面处理工程则需要在保持无菌性和产量以及配方兼容性之间取得平衡。

美洲、欧洲、中东和非洲以及亚太地区的区域製造能力、监管多样性和生态系统成熟度将如何影响战略采购和发展路径

区域洞察揭示了产能、监管细则和商业性动态如何影响製造商和申办者的采购和伙伴关係决策。在美洲，成熟的合约研发生产机构 (CDMO) 生态系统，以及生物技术创新者和大型製药申办者的高度位置，共同促进了快速的临床转化和强大的研发供应商合作。该地区的监管机构继续优先考虑核准后生产变更的可比性和清晰度，因此，与负责人的早期沟通和详尽的分析报告对于获得核准至关重要。

主要企业的能力和伙伴关係模式决定了其在溶瘤病毒製程开发、生产和监管支援方面的竞争优势

凭藉在细胞株设计、製程改进和分析创新方面的差异化能力，主要企业和专业服务供应商正日益塑造裂解病毒开发领域的营运格局。无论是新参与企业还是成熟的契约製造，都在投资于平台技术，以加速规模化生产，同时降低成本并维持产品品质。这些投资包括先进的一次性技术、封闭式处理系统和自动化分析技术，这些技术能够减少人工干预并提高可重复性。

为製造商、开发商和策略合作伙伴提供切实可行的、影响深远的建议，以提高溶瘤疗法计画的韧性、监管准备和可扩展生产能力。

产业领导者应优先考虑一系列切实可行的倡议，以提高裂解病毒领域的专案可预测性和商业化准备度。首先，在研发生命週期的早期阶段，将分析方法开发与效力研究设计相结合，以建立能够经受监管审查的稳健的可比性和批次放行标准。将分析方法开发与上游工程和下游製程最佳化并行开展，可以减少后期阶段出现意外问题，并缩短关键研究週期。

一套稳健透明的调查方法，结合了关键相关人员访谈、监管审查和技术流程分析，为营运和策略决策提供支援。

本研究采用多维度调查方法，结合了对高级技术和商业相关人员者的访谈、对监管指导文件的严格审查以及对製造和服务供应商能力的详细分析。主要定性访谈收集了製程开发科学家、品质保证和法规事务人员、供应链经理以及商业负责人的观点，以确保对整个开发生命週期有全面的了解。此外，还对同行评审文献、已发布的监管指导文件、技术白皮书和供应商规范进行了二次分析，检验技术声明并将其与行业最佳实践相结合。

对决定溶瘤病毒开发专案成败的营运、供应链和策略要务进行全面分析

分析表明，溶瘤病毒的研发正处于转折点。科学进步与操作技术的成熟融合，为改善患者疗效和商业性成功创造了实际机会。从早期概念到临床概念验证，最终实现商业化，关键在于细胞株设计、製程开发和分析方法的严谨整合。那些能够及早利用跨职能专业知识、优先开发检测方法并设计可扩展製程的机构，将能够降低技术风险并加速研发进程。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 溶瘤病毒生产和开发服务市场（按服务类型划分）

  • 分析服务
  • 细胞株构建
  • 灌装/包装
  • 製造业
    • 临床生产
    • 商业生产
    • 临床前生产
  • 製程开发
  • 纯化
  • 品管
  • 监管支持

第九章 溶瘤病毒生产与开发服务市场规模

  • 临床阶段
    • 第一阶段/第二阶段
    • 第三阶段
  • 商业的
  • 临床前

10. 溶瘤病毒生产和开发服务市场（按病毒类型划分）

  • 腺病毒
  • 单纯疱疹病毒
  • 麻疹病毒
  • 新城疫病毒
  • 呼肠孤病毒
  • 牛痘病毒

第十一章 溶瘤病毒生产与开发服务市场（依合约类型划分）

  • 联合调查
  • 服务型合约
  • 合资企业
  • 授权合约

12. 依最终用户分類的溶瘤病毒生产与开发服务市场

  • 学术研究机构
  • 生技公司
  • CRO（受託研究机构）
  • 医院
  • 製药公司

第十三章 溶瘤病毒生产与开发服务市场（依应用领域划分）

  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固态肿瘤
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 黑色素瘤

14. 各区域溶瘤病毒生产及开发服务市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 溶瘤病毒生产与开发服务市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国溶瘤病毒生产及开发服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国溶瘤病毒生产与开发服务市场

第十八章：中国溶瘤病毒生产与开发服务市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ABL, Inc.
  • AGC Biologics, Inc.
  • Amgen Inc.
  • Catalent, Inc.
  • Creative Biogene Co., Ltd.
  • Danaher Corporation
  • Elise Biopharma GmbH
  • Fujifilm Diosynth Biotechnologies
  • IDT Biologika GmbH
  • Lonza Group AG
  • Merck KGaA
  • Oncolys BioPharma, Inc.
  • Oncolytics Biotech Inc.
  • Oxford Biomedica plc
  • PsiOxus Therapeutics Ltd.
  • Recipharm AB
  • Replimune Group, Inc.
  • Sartorius AG
  • SillaJen, Inc.
  • Theriva Biologics, Inc.
  • Thermo Fisher Scientific Inc.
  • TILT Biotherapeutics Oy
  • Transgene SA
  • Viralytics Ltd.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FD8B3

The Oncolytic Virus Manufacturing & Development Services Market was valued at USD 360.33 million in 2025 and is projected to grow to USD 376.37 million in 2026, with a CAGR of 6.24%, reaching USD 550.61 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 360.33 million
Estimated Year [2026] USD 376.37 million
Forecast Year [2032] USD 550.61 million
CAGR (%) 6.24%

A concise, integrated introduction to the scientific, operational, and regulatory imperatives shaping oncolytic virus manufacturing and development pathways for stakeholders

The emergence of oncolytic viruses as a therapeutic modality has transformed cancer research and development, creating parallel demands across scientific, manufacturing, and regulatory domains. Developers pursuing oncolytic approaches now confront a dense intersection of cell biology, vector engineering, and clinical translation that requires harmonized upstream and downstream processes. As therapies move from bench toward clinical testing, the technical and operational complexity of producing safe, potent, and reproducible viral products increases substantially, demanding rigorous process controls, robust analytical frameworks, and scalable manufacturing strategies.

This introduction frames the critical levers for program success: selection and optimization of viral platforms, establishment of stable cell substrates and cell line development practices, development of validated purification and fill-finish processes, and alignment with evolving regulatory expectations for potency, purity, and safety. Moreover, the industry context is shaped by shifting commercial priorities, where sponsors must balance accelerated timelines with quality by design and risk-based approaches. In the current landscape, sponsors who integrate cross-functional expertise early can reduce downstream delays and ensure smoother transitions between preclinical, clinical, and commercial phases.

Transitioning from conceptual designs to operational plans requires disciplined technical transfer, strategic partner selection, and a clear understanding of contract structures that affect control, costs, and timelines. This document establishes that foundation by identifying core manufacturing and development considerations, mapping the primary areas where investment yields disproportionate returns, and clarifying how organizational choices influence the ability to deliver on clinical and commercial objectives.

How technological innovations, combination therapy strategies, and evolving regulatory expectations are reshaping oncolytic virus development and manufacturing decision making

Recent years have seen transformative shifts in the oncolytic virus landscape driven by technological advances, evolving clinical evidence, and market dynamics that reframe development strategies. Innovations in vector design, including improved tumor selectivity and immune-modulatory payloads, are expanding the therapeutic scope and prompting refinements to manufacturing workflows. Concurrently, improvements in analytical methods for identity, potency, and impurity profiling are enabling more informed process optimization and comparability assessments.

Clinical strategies have diversified as combination approaches with immune checkpoint inhibitors and other immunotherapies demonstrate additive or synergistic effects, encouraging sponsors to design manufacturing strategies that can support combination regimens and varied dosing paradigms. These scientific shifts are complemented by a maturing ecosystem of contract developers and manufacturers that offer modularized services across cell line development, process development, and commercial-scale production. As a consequence, sponsors now have more pathways to de-risk development through strategic outsourcing and alliance models that preserve agility while accessing specialized capabilities.

Regulatory expectations have also progressed, emphasizing lifecycle control, robust characterization, and post-approval manufacturing oversight. As a result, organizations are adopting quality-by-design principles and investing earlier in analytical development and control strategies to meet dossier expectations. Taken together, these trends create both opportunities and responsibilities for developers: adopt new capabilities rapidly while embedding rigorous process and quality systems to ensure reproducible clinical performance and patient safety.

Assessing the cumulative supply chain, procurement, and operational consequences of tariff changes introduced in 2025 on oncolytic virus development and manufacturing networks

The introduction and escalation of United States tariffs in 2025 have imposed new considerations across international supply chains that support oncolytic virus manufacturing. Procurement of specialized raw materials, single-use components, and certain instrumentation has encountered additional cost pressures and sourcing complexities, prompting organizations to reassess supplier footprints and logistics models. In response, many developers and service providers have intensified efforts to diversify suppliers, qualify alternate materials, and renegotiate terms to preserve continuity of supply while managing cost inflation.

These tariff-driven dynamics have also influenced nearshoring and reshoring dialogues, with some sponsors evaluating regional manufacturing strategies to reduce exposure to cross-border trade risks. Such shifts increase the value of local manufacturing capacity but may also require capital investments in facilities, workforce training, and regulatory harmonization efforts. Simultaneously, contract manufacturers are recalibrating procurement strategies and inventory policies to buffer clients from supply interruptions, which in turn affects lead times and working capital requirements.

Importantly, the cumulative impact of tariff changes has accelerated adoption of strategic risk management practices across sponsor portfolios. Portfolio prioritization, component standardization, and early supplier engagement now occupy more prominent roles in program planning. As stakeholders adapt, they are increasingly focused on building resilient supply chains that combine diversified sourcing, regional manufacturing options, and contractual protections to mitigate price volatility and sustain uninterrupted development timelines.

Actionable segmentation-based insights that align service types, viral platforms, end users, applications, contract models, and scale requirements to development priorities

A nuanced segmentation framework clarifies where technical needs, procurement choices, and partner models diverge across the oncolytic virus market. When considering service type, demands range from analytical services and cell line development to fill and finish, manufacturing, process development, purification, quality control, and regulatory support, with manufacturing itself differentiating by clinical, commercial, and preclinical stages and clinical manufacturing subdivided into Phase I/II and Phase III needs. Each service type imposes different performance metrics: analytical work must deliver sensitive and specific assays, cell line development must ensure stability and scalability, and fill-finish operations must balance aseptic integrity with throughput and formulation compatibility.

Scale-based segmentation further refines operational requirements as clinical, commercial, and preclinical programs exhibit distinct throughput, quality control depth, and process robustness expectations; within clinical scale, Phase I/II demands rapid iterative flexibility while Phase III requires greater process consistency and validation readiness. Virus type segmentation illustrates modality-specific manufacturing considerations: adenovirus constructs often require distinct upstream cell systems and purification strategies compared with herpes simplex virus, measles virus, Newcastle disease virus, reovirus, or vaccinia virus platforms, each presenting unique stability, host-cell impurity, and potency assay challenges.

End-user segmentation captures differing objectives and operational sophistication across academic research institutes, biotech companies, contract research organizations, hospitals, and pharmaceutical companies; academic groups may prioritize proof-of-concept flexibility while commercial sponsors emphasize regulatory compliance and supply chain robustness. Application segmentation highlights therapeutic focus areas in hematological malignancies versus solid tumors, with hematological indications such as leukemia, lymphoma, and multiple myeloma requiring specialized dosing and distribution considerations, and solid tumor indications like breast, colorectal, lung cancers, and melanoma demanding targeted delivery strategies and tumor microenvironment considerations. Contract type segmentation delineates how collaborative research, fee-for-service, joint ventures, and license agreements distribute technical responsibilities, risk, and IP control, thereby influencing partner selection, timeline expectations, and the scope of technology transfer activities. Together, this segmented view enables sponsors and service providers to align capabilities to program stage, modality, and strategic intent to optimize resource allocation and development trajectories.

How regional manufacturing capacity, regulatory diversity, and ecosystem maturity across the Americas, EMEA, and Asia-Pacific influence strategic sourcing and development pathways

Regional insights reveal where capacity, regulatory nuance, and commercial dynamics shape sourcing and partnership decisions for manufacturers and sponsors alike. In the Americas, a well-developed ecosystem of contract development and manufacturing organizations, coupled with a dense concentration of biotech innovators and large pharmaceutical sponsors, supports rapid clinical translation and strong developer-vendor collaboration. Regulatory agencies in the region continue to emphasize clarity around comparability and post-approval manufacturing changes, necessitating early engagement with reviewers and thorough analytical packages to support approvals.

Europe, Middle East & Africa present a heterogeneous landscape where centers of excellence coexist with emerging research hubs, and where regulatory frameworks across jurisdictions require harmonized clinical and manufacturing strategies that account for cross-border differences. Sponsors operating in this region benefit from engaging local regulatory expertise and leveraging established manufacturing clusters for clinical and commercial supply, while also anticipating variable reimbursement and health-system access considerations that can influence go-to-market sequencing.

Asia-Pacific is characterized by rapid expansion of manufacturing capacity, increasing local technical expertise, and a growing pipeline of biologics and advanced therapies. Governments and regional stakeholders are investing in biotechnology infrastructure, which expands options for clinical and commercial manufacturing but also requires careful navigation of local regulatory pathways and quality expectations. Across all regions, sponsors must weigh advantages of localized capacity against the need for global comparability, ensuring that process controls and analytical methods support multi-region registration strategies and long-term supply resilience.

Key company-level capabilities and partnership models that determine competitive advantage in oncolytic virus process development, manufacturing, and regulatory support

Leading companies and specialized service providers increasingly define the operational contours of the oncolytic virus development landscape through differentiated capabilities in cell line engineering, process intensification, and analytical innovation. Market entrants and established contract manufacturers alike are investing in platform technologies that accelerate scale-up while reducing costs and preserving product quality. These investments include advanced single-use technologies, closed processing systems, and automated analytics that reduce manual intervention and improve reproducibility.

Strategic partnerships between developers and manufacturers are becoming more structured and longer term, reflecting the need to manage complex transfers and scale transitions. Companies that offer integrated service suites-from early-stage cell line development through clinical manufacturing and regulatory support-tend to attract programs that value continuity and reduced technology transfer risk. At the same time, nimble niche providers specializing in a particular virus platform or analytical domain can offer differentiated value for sponsors with specialized technical needs.

Competitive differentiation increasingly centers on proven regulatory track records, demonstrated capacity to support multi-phase programs, and the ability to adapt processes for combination therapies and novel formulations. Companies that combine technical depth with robust quality systems and transparent communication practices position themselves as preferred partners for both emerging biotech sponsors and established pharmaceutical firms seeking reliable operational partners.

Practical, high-impact recommendations for manufacturers, developers, and strategic partners to improve program resilience, regulatory readiness, and scalable production of oncolytic therapies

Industry leaders should prioritize a set of pragmatic actions to strengthen program predictability and commercial readiness in the oncolytic virus space. First, integrate analytical development and potency assay design early in the development lifecycle to enable robust comparability and batch-release criteria that will withstand regulatory scrutiny. Embedding analytical development alongside upstream and downstream optimization reduces late-stage surprises and shortens timelines for pivotal studies.

Second, adopt flexible manufacturing architectures that allow seamless transitions between preclinical, clinical, and commercial scales; this includes investing in platform process elements that can be scaled with minimal re-validation, using single-use systems where appropriate, and developing clear technology transfer documentation to mitigate risks during partner handoffs. Third, actively manage supply chain resilience by qualifying multiple suppliers for critical raw materials, evaluating regional manufacturing options, and including contractual protections that address tariff and trade volatility. These actions reduce program susceptibility to disruption and provide greater control over lead times and costs.

Finally, cultivate collaborative contracting models that balance sponsor oversight with manufacturer expertise, whether through fee-for-service agreements, joint ventures, or licensing arrangements. These models should align incentives around timelines, quality metrics, and intellectual property management to foster long-term partnerships that support successful commercialization. Taken together, these recommendations provide an actionable roadmap for leaders seeking to translate scientific promise into sustainable therapeutic programs.

A robust, transparent research methodology combining primary stakeholder interviews, regulatory review, and technical process analysis to support operational and strategic decision making

This research applied a multi-dimensional methodology that combined primary interviews with senior technical and commercial stakeholders, rigorous review of regulatory guidance documents, and detailed mapping of manufacturing and service provider capabilities. Primary qualitative interviews captured perspectives from process development scientists, quality assurance and regulatory affairs leads, supply chain managers, and commercial officers to ensure a holistic view across the development lifecycle. These insights were complemented by secondary analysis of peer-reviewed literature, published regulatory guidance, technical white papers, and vendor specifications to validate technical assertions and contextualize industry best practices.

Technical assessments focused on core process elements: cell line development practices, upstream and downstream processing choices, purification and formulation considerations, fill-finish constraints, and analytical method development. Case-based comparisons illustrated how different virus platforms influence process steps and regulatory expectations. Supply chain and procurement analyses evaluated the implications of tariff changes, material lead times, and regional manufacturing capacity. Throughout the analysis, findings were corroborated through triangulation of sources, cross-validated with domain experts, and synthesized into actionable recommendations that reflect both technical feasibility and commercial realities.

Methodological limitations were addressed by transparently documenting assumptions, noting areas where proprietary data were not available, and identifying topics where ongoing surveillance of regulatory updates and technological advances is required. The result is a pragmatic, evidence-based study designed to inform near-term operational decisions and longer-term strategic planning for stakeholders engaged in oncolytic virus development.

Concluding synthesis on the operational, supply chain, and strategic imperatives that collectively determine the success of oncolytic virus development programs

This analysis concludes that oncolytic virus development sits at an inflection point where scientific advances and operational sophistication converge to create tangible opportunities for improved patient outcomes and commercial success. The pathway from early-stage concept to clinical proof-of-concept and eventual commercialization depends on disciplined integration of cell line engineering, process development, and analytical rigor. Organizations that engage cross-functional expertise early, prioritize assay development, and design scalable processes stand to reduce technical risk and accelerate timelines.

Supply chain dynamics, including the impacts of recent tariff changes, have introduced an additional layer of complexity that requires sponsors to proactively manage supplier networks and consider regional manufacturing strategies where appropriate. Strategic contracting and partnership models that allocate responsibilities and align incentives can mitigate execution risks and preserve program momentum. Moreover, modality-specific considerations-such as the differing upstream and purification needs of adenovirus versus herpes simplex or vaccinia platforms-demand tailored manufacturing solutions rather than one-size-fits-all approaches.

In sum, the successful development of oncolytic virus therapies will be driven by a combination of technical excellence, supply chain resilience, and strategic partnerships that together enable reliable production, regulatory compliance, and effective clinical execution. Stakeholders who adopt these principles will be better positioned to translate scientific promise into sustained therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncolytic Virus Manufacturing & Development Services Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Cell Line Development
  • 8.3. Fill & Finish
  • 8.4. Manufacturing
    • 8.4.1. Clinical Manufacturing
    • 8.4.2. Commercial Manufacturing
    • 8.4.3. Preclinical Manufacturing
  • 8.5. Process Development
  • 8.6. Purification
  • 8.7. Quality Control
  • 8.8. Regulatory Support

9. Oncolytic Virus Manufacturing & Development Services Market, by Scale

  • 9.1. Clinical
    • 9.1.1. Phase I/II
    • 9.1.2. Phase III
  • 9.2. Commercial
  • 9.3. Preclinical

10. Oncolytic Virus Manufacturing & Development Services Market, by Virus Type

  • 10.1. Adenovirus
  • 10.2. Herpes Simplex Virus
  • 10.3. Measles Virus
  • 10.4. Newcastle Disease Virus
  • 10.5. Reovirus
  • 10.6. Vaccinia Virus

11. Oncolytic Virus Manufacturing & Development Services Market, by Contract Type

  • 11.1. Collaborative Research
  • 11.2. Fee-for-Service
  • 11.3. Joint Ventures
  • 11.4. License Agreements

12. Oncolytic Virus Manufacturing & Development Services Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Biotech Companies
  • 12.3. Contract Research Organizations
  • 12.4. Hospitals
  • 12.5. Pharmaceutical Companies

13. Oncolytic Virus Manufacturing & Development Services Market, by Application

  • 13.1. Hematological Malignancies
    • 13.1.1. Leukemia
    • 13.1.2. Lymphoma
    • 13.1.3. Multiple Myeloma
  • 13.2. Solid Tumors
    • 13.2.1. Breast Cancer
    • 13.2.2. Colorectal Cancer
    • 13.2.3. Lung Cancer
    • 13.2.4. Melanoma

14. Oncolytic Virus Manufacturing & Development Services Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oncolytic Virus Manufacturing & Development Services Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oncolytic Virus Manufacturing & Development Services Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Oncolytic Virus Manufacturing & Development Services Market

18. China Oncolytic Virus Manufacturing & Development Services Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ABL, Inc.
  • 19.6. AGC Biologics, Inc.
  • 19.7. Amgen Inc.
  • 19.8. Catalent, Inc.
  • 19.9. Creative Biogene Co., Ltd.
  • 19.10. Danaher Corporation
  • 19.11. Elise Biopharma GmbH
  • 19.12. Fujifilm Diosynth Biotechnologies
  • 19.13. IDT Biologika GmbH
  • 19.14. Lonza Group AG
  • 19.15. Merck KGaA
  • 19.16. Oncolys BioPharma, Inc.
  • 19.17. Oncolytics Biotech Inc.
  • 19.18. Oxford Biomedica plc
  • 19.19. PsiOxus Therapeutics Ltd.
  • 19.20. Recipharm AB
  • 19.21. Replimune Group, Inc.
  • 19.22. Sartorius AG
  • 19.23. SillaJen, Inc.
  • 19.24. Theriva Biologics, Inc.
  • 19.25. Thermo Fisher Scientific Inc.
  • 19.26. TILT Biotherapeutics Oy
  • 19.27. Transgene S.A.
  • 19.28. Viralytics Ltd.
  • 19.29. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FILL & FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FILL & FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FILL & FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I/II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I/II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I/II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MEASLES VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MEASLES VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MEASLES VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLLABORATIVE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLLABORATIVE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLLABORATIVE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FEE-FOR-SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FEE-FOR-SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FEE-FOR-SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY JOINT VENTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY JOINT VENTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY JOINT VENTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LICENSE AGREEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LICENSE AGREEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LICENSE AGREEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ONCOLYTIC VIRUS MANUFACTURING &